www.medpagetoday.com Open in urlscan Pro
23.57.90.41  Public Scan

Form analysis
1 forms found in the DOM

/search

<form role="search" action="/search" class="active" id="global-nav-search-bar">
  <div class="input_container">
    <label for="global-nav-search-input" class="screen-readers-only">Search</label>
    <input id="global-nav-search-input" name="q" data-name="header-search" type="search" autocomplete="off" class="search_field searchField" placeholder="Enter Search Terms">
  </div>
</form>

Text Content

 * Edit Profile
 * Manage Subscriptions
 * CME Tracker
 * Log Out

Login
Sign Up
search
Search
 * Specialties
   Back
    * Allergy & Immunology
    * Anesthesiology
    * Cardiology
    * Critical Care
    * Dermatology
    * Emergency Medicine
    * Endocrinology
    * Gastroenterology
    * Genetics
    * Geriatrics
    * HIV / AIDS
    * Hospital-Based Medicine
    * Infectious Disease
    * Nephrology
    * Neurology
    * Nursing
    * OB / GYN
    * Oncology / Hematology
    * Ophthalmology
    * Orthopedics
    * Pain Management
    * Pathology
    * Pediatrics
    * Pharmacy
    * Primary Care
    * Psychiatry
    * Pulmonology
    * Radiology
    * Rheumatology
    * Surgery
    * Transplantation
    * Urology

 * Perspectives
 * Health Policy
 * Meetings
 * Special Reports
 * Break Room
 * Conditions
   Back
    * Condition Centers
    * Making the Rounds
    * Medical Journeys

 * Society Partners
   Back
    * AAD Reading Room
    * ACR Reading Room
    * AGA Reading Room
    * ASCO Reading Room
    * Endocrine Society Reading Room
    * IDSA Reading Room

 * CME
 * Healthcare Jobs
 * Synopsi

Endocrinology > Type 1 Diabetes


LOW-DOSE SEMAGLUTIDE CAN EASE INSULIN NEED IN EARLY T1D, SMALL SERIES SHOWS


— ALL 10 PATIENTS WERE ABLE TO ELIMINATE PRANDIAL INSULIN USE WITHIN 3 MONTHS

by Kristen Monaco, Senior Staff Writer, MedPage Today September 6, 2023


MedpageToday

Share on Facebook. Opens in a new tab or window
Share on X. Opens in a new tab or window
Share on LinkedIn. Opens in a new tab or window

email article


When used very early on in type 1 diabetes, a GLP-1 receptor agonist may help
reduce the need for insulin, a small case series suggested.

Ten adults with a new type 1 diabetes diagnosis initially received a 0.125-mg
dose of weekly semaglutide (Ozempic), which was adjusted up to a maximum of 0.5
mg per week as prandial insulin was adjusted down.

Within 3 months of starting semaglutide, all of the patients were completely off
prandial insulin. Within 6 months, seven patients were also able to eliminate
basal insulin, reported Paresh Dandona, MD, PhD, of the State University of New
York at Buffalo in Williamsville, New York, and colleagues, who detailed their
findings in a New England Journal of Medicineopens in a new tab or window
correspondence.



"In all, our preliminary observations support the need for prospective,
randomized clinical trials with larger numbers of patients to investigate this
approach further," the researchers suggested.

Though widely used for type 2 diabetes and obesity, no GLP-1 receptor agonists
or SGLT2 inhibitors are currently approved by the FDA for type 1 diabetes. While
some agents have been submitted to the agencyopens in a new tab or window for
review, none have actually nabbed a type 1 diabetes indication, often due to
concerns about diabetic ketoacidosis and hypoglycemia from the agents' dramatic
glucose lowering capabilities.

The current case series followed patients ages 21 to 39 at the State University
of New York at Buffalo from 2020 to 2022. Half were female, all but one were
white, and their average baseline body mass index was 25.1. Four initially
presented with diabetic ketoacidosis at the time of diagnosis while the others
presented with polyuria, polydipsia, and weight loss. A total of nine patients
had antibodies against glutamic acid decarboxylase, and one had autoantibodies
against islet antigen 2.



Patients were started on semaglutide within 3 months of their diagnosis, as
"most patients with new-onset type 1 diabetes have substantial intact beta-cell
reserve," the researchers noted. While medication doses were being adjusted,
carbohydrate intake was restricted for all patients.

Mean HbA1c dropped from 11.7±2.1% at baseline down to 5.9±0.3% by the 6-month
mark of semaglutide treatment. This continued to drop a bit more, falling to
5.7±0.4% at 12 months.

Patients on semaglutide also saw a significant rise in mean fasting C-peptide
levels, from 0.65±0.33 ng/mL at baseline up to 1.05±0.40 ng/mL by the end of the
study and patients spent 89±3% of time in range as measured by continuous
glucose monitoring.


MEDICAL NEWS FROM AROUND THE WEB

STAT
1
The WHO and drug regulators want to reformulate the flu vaccine. It’s easier
said than done
opens in a new tab or window
KevinMD.com
2
Why new cancer treatments cannot save us
opens in a new tab or window
CNN
3
It’s not just ‘Sephora kids.’ 20-somethings are paying up for cosmetic
procedures to prevent aging | CNN
opens in a new tab or window

As they had no control arm, the researchers compared their HbA1c data with the
control groups of four studies involving patients with early type 1 diabetes,
where initial improvement in HbA1c was only observed during the first 6 months.



"Thereafter, they all showed an increase in the glycated hemoglobin level, a
finding that was consistent with the end of the so-called 'honeymoon period' in
the treatment of early type 1 diabetes," Dandona and coauthors wrote.

As is the concern in type 1 diabetes, the researchers pointed out that only mild
hypoglycemia was seen during the semaglutide dose titration. After the dose was
stabilized, none of the patients experienced any episodes of hypoglycemia.
Likewise, there were no events of diabetic ketoacidosis or other serious adverse
events.

At baseline, the average total insulin dose was 0.35±0.11 U/kg, while basal and
bolus insulin doses were 0.21±0.12 U/kg and 0.15±0.09 U/kg, respectively.



 * Kristen Monaco is a senior staff writer, focusing on endocrinology,
   psychiatry, and nephrology news. Based out of the New York City office, she’s
   worked at the company since 2015.

Disclosures

Dandona reported no disclosures. A co-author reported relationships with Eli
Lilly and Novo Nordisk.

Primary Source

New England Journal of Medicine

Source Reference: opens in a new tab or windowDandona P, et al "Semaglutide in
early type 1 diabetes" N Engl J Med 2023; DOI: 10.1056/NEJMc2302677.

Share on Facebook. Opens in a new tab or window
Share on X. Opens in a new tab or window
Share on LinkedIn. Opens in a new tab or window

email article
3 Comments Please enable JavaScript to view the comments powered by Disqus.


MEDICAL NEWS FROM AROUND THE WEB

STAT
1
The WHO and drug regulators want to reformulate the flu vaccine. It’s easier
said than done
opens in a new tab or window
KevinMD.com
2
Why new cancer treatments cannot save us
opens in a new tab or window
CNN
3
It’s not just ‘Sephora kids.’ 20-somethings are paying up for cosmetic
procedures to prevent aging | CNN
opens in a new tab or window






MEDICAL NEWS FROM AROUND THE WEB

STAT
1
The WHO and drug regulators want to reformulate the flu vaccine. It’s easier
said than done
opens in a new tab or window
KevinMD.com
2
Why new cancer treatments cannot save us
opens in a new tab or window
CNN
3
It’s not just ‘Sephora kids.’ 20-somethings are paying up for cosmetic
procedures to prevent aging | CNN
opens in a new tab or window
Forbes
4
The Hepatitis C Crisis Epitomizes The Problems With U.S. Healthcare
opens in a new tab or window
Pediatrics
5
Vaccine Effectiveness Against Long COVID in Children.
opens in a new tab or window
Annals of Internal Medicine
6
Gabapentinoids and Risk for Severe Exacerbation in Chronic Obstructive Pulmonary
Disease : A Population-Based Cohort Study.
opens in a new tab or window


RECOMMENDED FOR YOU

1

Second Opinions
How Should Health Plans Respond to Surging Interest in Weight Loss Drugs?
2

Primary Care
FDA Clears Wegovy, Other GLP-1 Drugs of Suicidality Risk for Now
3

Primary Care
More Kids Getting Their Hands on Nonprescription Weight-Loss Products
4

Rheumatology
When Women's Fertility Begins and Ends Seems Important for RA Development
5

Oncology/Hematology
More Evidence Linking ADT for Prostate Cancer to Adverse Neurocognitive Effects
6

Endocrinology
T1D Trial Paused After Deaths; Mounjaro Not Just Cosmetic; Late-Stage Hot Flash
Win


Visit us on Facebook. Opens in a new tab or window
Visit us on X. Opens in a new tab or window
Visit us on Instagram. Opens in a new tab or window
Visit us on LinkedIn. Opens in a new tab or window
Visit us on TikTok. Opens in a new tab or window
Visit us on YouTube. Opens in a new tab or window
Subscribe for Free
About Help Center Terms of Use Privacy Policy
Do Not Sell My Personal Information Advertise with us AdChoices Accessibility
Statement
visit everydayhealthgroup.com

visit healthecareers.com/
visit medpagetoday.com
visit primeinc.org

The material on this site is for informational purposes only, and is not a
substitute for medical advice, diagnosis or treatment provided by a qualified
health care provider.
© 2005–2024 MedPage Today, LLC, a Ziff Davis company. All rights reserved.
Medpage Today is among the federally registered trademarks of MedPage Today, LLC
and may not be used by third parties without explicit permission.